Pappalysin Regulator

Abstract

A method is provided of decreasing or increasing the activity of a Pappalysin polypeptide by decreasing or increasing the level of interacting Pappalysin and stanniocalcin polypeptides. A method is also provided of preventing, treating or ameliorating a clinical condition in a mammalian subject, such as a human being, said method comprising administering to said mammalian subject, such as human being an effective amount of a stanniocalcin polypeptide. Moreover, a method is provided of preventing, treating or ameliorating a clinical condition in a mammalian subject, such as a human being, said method comprising administering to said mammalian subject, such as human being an effective amount of an agent capable of antagonizing interaction of a stanniocalcin polypeptide with a Pappalysin polypeptide.

1 .- 4 . (canceled) 
     
     
         5 . A method of decreasing or increasing the activity of a Pappalysin polypeptide comprising the step of decreasing or increasing the level of interacting Pappalysin and stanniocalcin polypeptides. 
     
     
         6 . The method according to  claim 5 , wherein an agent capable of decreasing or increasing the level of stanniocalcin polypeptide and/or the level of interacting Pappalysin and stanniocalcin polypeptides is provided to a sample comprising said Pappalysin polypeptide. 
     
     
         7 . The method according to  claim 5 , wherein
 a. the activity of Pappalysin polypeptide is decreased by increasing the level of a stanniocalcin polypeptide, and   b. the activity of Pappalysin polypeptide increased by decreasing the level of a stanniocalcin polypeptide.   
     
     
         8 . The method according to  claim 5 , wherein the activity of a Pappalysin polypeptide is increased by providing an agent, which antagonizes the interaction of stanniocalcin with Pappalysin. 
     
     
         9 . The method according to  claim 8 , wherein said agent is a stanniocalcin directed siRNA or an antibody capable of antagonizing interaction of a stanniocalcin polypeptide with a Pappalysin polypeptide. 
     
     
         10 . The method according to  claim 5 , wherein the activity of Pappalysin polypeptide is inhibited by contacting said Pappalysin with a stanniocalcin polypeptide. 
     
     
         11 .- 12 . (canceled) 
     
     
         13 . A method of preventing, treating or ameliorating a clinical condition in a mammalian subject, said method comprising administering to said mammalian subject, an effective amount of a stanniocalcin polypeptide. 
     
     
         14 . The method according to  claim 5 , wherein the activity of a Pappalysin polypeptide is inhibited. 
     
     
         15 . The method according to  claim 14 , wherein the activity of said Pappalysin polypeptide is inhibited by interaction of a Pappalysin polypeptide with at least one stanniocalcin polypeptide. 
     
     
         16 . The method according to  claim 13 , wherein said clinical condition is a proliferative disorder. 
     
     
         17 . (canceled) 
     
     
         18 . The method according to  claim 13 , wherein said clinical condition is restenosis, atherosclerosis, ovulation, fibrosis, or cancer, or a vascular disease, or a condition of increased fluid accumulation, or wherein said clinical condition is related to human reproduction. 
     
     
         19 .- 22 . (canceled) 
     
     
         23 . The method according to  claim 16 , wherein said proliferative disorder is associated with Pappalysin-meditated cleavage of an Insulin-like growth factor-binding protein (IGFBP). 
     
     
         24 . The method according to  claim 18 , wherein said cancer is ovarian cancer, testicular cancer, lung cancer, or any cancer of the digestive system, including ventricular cancer, colon cancer, small bowel cancer and rectal cancer. 
     
     
         25 .- 26 . (canceled) 
     
     
         27 . A method of preventing, treating or ameliorating a clinical condition in a mammalian subject, said method comprising administering to said mammalian subject an effective amount of an agent capable of antagonizing interaction of a stanniocalcin polypeptide with a Pappalysin polypeptide. 
     
     
         28 . The method of  claim 27 , wherein a proliferative process is stimulated. 
     
     
         29 . The method according to  claim 27 , wherein said clinical condition is growth of bone or bone remodeling, or wherein said clinical condition is a wound and said treatment or amelioration is wound healing. 
     
     
         30 .- 68 . (canceled) 
     
     
         69 . A method of determining a clinical condition, said method comprising detecting interacting Pappalysin and stanniocalcin polypeptides. 
     
     
         70 .- 73 . (canceled) 
     
     
         74 . The method according to  claim 69 , wherein said clinical condition is a cancer, such as ovarian cancer, testicular cancer, lung cancer, or any cancer of the digestive system, including ventricular cancer, colon cancer, small bowel cancer and rectal cancer. 
     
     
         75 .- 76 . (canceled)